hVIVO plc (LSE:HVO), a contract research organisation specialising in human challenge trials and early-stage drug development, has confirmed that it will publish its final results for the year ended 31 December 2025 on 15 April 2026.
The results announcement will be accompanied by presentations for equity analysts and an online investor briefing hosted by chief executive Yamin ‘Mo’ Khan and chief financial officer Stephen Pinkerton. The sessions will provide additional insight into the company’s performance and operations across its clinical research platform.
Management said the engagement reflects the company’s continued efforts to maintain active communication with the investment community while highlighting progress across its human challenge studies, laboratory services and early-phase clinical trial activities.
The company’s outlook is supported by strong financial performance and an attractive valuation profile. Solid revenue growth and relatively low leverage position the business favourably within the biotechnology services sector. While technical indicators suggest bullish momentum, the share price remains below certain longer-term moving averages, which may act as near-term resistance. A low price-to-earnings ratio combined with a reasonable dividend yield also adds to the company’s appeal for value and income-focused investors.
More about hVIVO plc
hVIVO plc is a full-service early-phase contract research organisation focused on human challenge clinical trials in infectious and respiratory diseases. The company operates the world’s largest quarantine facility in London and provides virology and immunology laboratory services through its hLAB division. It also runs early-phase clinical trial units in Germany through its CRS subsidiary and offers consulting and biometry services via Venn Life Sciences, supporting pharmaceutical and biotechnology clients worldwide.
Leave a Reply